Zhimin Zhang
State Key Laboratory Of Bioactive Molecules And Druggability Assessment
Guangzhou, 510632, China
Guangzhou, 510632, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Unique Cysteine-Directed Covalent Inhibition of PRMT1 Suppresses Breast Tumorigenesis.
Journal: Journal of medicinal chemistry
Published: June 17, 2026
Discovery of SKP2-Recruiting PROTACs for Target Protein Degradation.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: August 11, 2025
The design and synthesis of selective and potent selenium-containing KRASG12D inhibitors.
Journal: European journal of medicinal chemistry
Published: May 05, 2025
JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo.
Journal: Molecules (Basel, Switzerland)
Published: August 31, 2022
ENO2-derived phosphoenolpyruvate functions as an endogenous inhibitor of HDAC1 and confers resistance to antiangiogenic therapy.
Journal: Nature metabolism
Published: April 14, 2022
Characterization of an aromatic trifluoromethyl ketone as a new warhead for covalently reversible kinase inhibitor design.
Journal: Bioorganic & medicinal chemistry
Published: July 18, 2021
Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors.
Journal: International journal of antimicrobial agents
Published: April 28, 2020
Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors.
Journal: European journal of medicinal chemistry
Published: March 20, 2020
Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors.
Journal: EMBO molecular medicine
Published: October 08, 2019
Showing 1-9 of 9
Last Updated: 09/26/2026